Edition:
United States

Pharming Group NV (PHAR.AS)

PHAR.AS on Amsterdam Stock Exchange

0.29EUR
11:35am EDT
Change (% chg)

€0.00 (+0.00%)
Prev Close
€0.29
Open
€0.29
Day's High
€0.29
Day's Low
€0.29
Volume
2,399,189
Avg. Vol
6,872,141
52-wk High
€0.37
52-wk Low
€0.15

Latest Key Developments (Source: Significant Developments)

Pharming Group FY net loss widens to 17.5 million euros
Thursday, 9 Mar 2017 01:00am EST 

Pharming Group NV : FY revenue from product sales 13.7 million euros ($14.43 million) versus 8.6 million euros year ago . FY revenue 15.9 million euros versus 10.8 million euros year ago . FY net loss 17.5 million euros versus loss of 10.0 million euros year ago . Cash position, including restricted cash, 32.1 million euros at year-end 2016 versus 31.8 million euros at year-end 2015 . For 2017 sees continued growth in revenues from sales of RUCONEST, mainly driven by the US operations .For 2017 sees achievement of positive quarterly operating results in the course of the year.  Full Article

Pharming Group announces additional conversions of its amortizing bonds
Friday, 3 Feb 2017 01:00am EST 

Pharming Group NV : Announces additional conversions of its amortizing bonds . Total number of shares issued in conversions is 7,558,479 ordinary shares . Amount of amortizing bonds outstanding is reduced from 45.0 million euros ($48.4 million) to 39.7 million euros .No cash payment was required in respect of first instalment of bonds due on Feb 1, 2017 and second installment due on March 1, 2017 has now also been mostly settled.  Full Article

Pharming Group announces issue of new stock
Thursday, 26 Jan 2017 03:23am EST 

Pharming Group NV : Announces issue of new stock as a result of conversion of amortizing bonds . Total number of shares issued in conversions is 10,823,881 ordinary shares . Amount of amortizing bonds outstanding is reduced from 45.0 million euros ($48.32 million) to 41.9 million euros .New shares represent 2.38 pct of issued share capital of company prior to issue, and 2.32 pct of enlarged issued share capital of company.  Full Article

EC amends marketing authorisation for Pharming Group's Ruconest to include self-administration
Monday, 16 Jan 2017 04:02am EST 

Pharming Group NV : European Commission amends marketing authorisation for Ruconest to include self-administration . European Commission adopted Commission Implementing Decision to amend marketing authorisation for Ruconest to include self administration using Ruconest Administration Kit . Decision allows for self-administration of Ruconest for acute hereditary angioedema (HAE) attacks by adolescents and adults with a new custom-designed Ruconest Administration Kit .Ruconest Administration Kit will become available for use in various EU markets, following approval of educational materials by local authorities, expected over coming 1-3 mths.  Full Article

Pharming Group announces completion of acquisition of all north American commercialization rights for Ruconest from Valeant
Thursday, 8 Dec 2016 01:00am EST 

Pharming Group NV : Pharming Group announces completion of acquisition of all north American commercialization rights for Ruconest from Valeant . Cash position after closing of deal and payment of all transaction costs strengthened to 34.3 million euros ($36.94 million) . Funding through a combination of new equity, straight debt and new convertible bonds of 104 million euros before costs . $125 million deal value, with an upfront fee paid to Valeant of $60 million, and future self-funding sales milestone payments up to a further $65 million in total . Immediate and substantial positive impact on Pharming's operational results and near-term profitability .Annualized run rate of sales, increased from $35 million in Q3 2016 to more than $40 million, based on average of most recent two months of sales (October and November).  Full Article

EMA says CHMP recommends approving Afstyla
Friday, 11 Nov 2016 07:11am EST 

EU Medicines Agency : Recommendations for November 2016 . Vemlidy, also known as tenofovir alafenamide received positive opinion from CHMP for treatment of chronic Hepatitis B .CHMP recommended granting marketing authorisation for Afstyla for prevention, treatment of bleeding in patients with Haemophilia A.  Full Article

Pharming Group expects to become profitable at operating level in 2017
Thursday, 27 Oct 2016 02:15am EDT 

Pharming Group NV : Pharming reports on financial results for the first nine months of 2016 . Sales in the US in the first nine months of 2016 were up by approximately 16 pct compared to the same period last year, and up 66 pct compared to the first half year of 2016 . 9 month gross profit increased by 15 pct relative to the same period last year, which was previously Pharming's most successful period, and up 67 pct compared to the first half year of 2016 . 9 month revenue 8.7 million euros ($9.5 million) versus 8.5 million euros a year ago . Operating loss at September 30 9.4 million euros versus a loss of 9.1 million euros a year ago . "We expect that both sales and gross profits will continue to improve during the remainder of the year" - CEO ."We would expect to become profitable at the operating level during 2017" - CEO.  Full Article

Pharming Group 8-month product sales rise to 6.2 million euros
Monday, 3 Oct 2016 01:00am EDT 

Pharming Group Nv : 8-month product sales 6.2 million euros ($6.97 million)versus 5.6 million euros year ago . 8-month operating loss 8.3 million euros versus loss of 8.1 million euros year ago . Expect that both sales and gross profits will continue to improve during remainder of year and that investments in research and development will continue to increase gradually. .Would expect to become profitable at operating level during 2017.  Full Article

Valeant Pharmaceuticals Q2 GAAP loss per share $0.88
Tuesday, 9 Aug 2016 05:46am EDT 

Valeant Pharmaceuticals International Inc : Valeant Pharmaceuticals reports second quarter 2016 financial results . Sees FY 2016 revenue $9.9 billion to $10.1 billion . Q2 earnings per share view $1.48 -- Thomson Reuters I/B/E/S . Q2 GAAP loss per share $0.88 . "we have taken steps to streamline our portfolio in Q2" . Entered into a definitive agreement to divest all north american commercialization rights to Ruconest to Pharming Group N.V. . Sold, or agreed to sell, brodalumab EU rights, synergetics USA OEM business, and Ruconest® for a total combined upfront payment of $181 million . Pharming will also pay valeant certain sales-based milestone payments of up to $65 million . Brodalumab EU rights,synergetics USA OEM business,Ruconest deal includes additional consideration up to $329 million for approval,sales milestones . Total revenues decreased 11% to $2.42 billion in Q2 of 2016 . Q2 earnings per share view $1.44, revenue view $2.45 billion -- Thomson Reuters I/B/E/S . Valeant Pharmaceuticals international inc qtrly adjusted earnings per share $1.40 . Company is reconfirming its full year 2016 guidance . Announcing new strategic direction for Valeant, which will involve reorganizing our company and reporting segments . Pharming will pay valeant aggregate consideration of up to $125 million, including an upfront fee of $60 million payable upon closing.  Full Article

Pharming Group H1 operating loss at 6.2 million euros
Thursday, 28 Jul 2016 01:00am EDT 

Pharming Group Nv : H1 revenues 5.3 million euros ($5.86 million) versus 5.2 million euros year ago . H1 operating loss 6.2 million euros versus loss of 6.1 million euros year ago . H1 total cash and cash equivalent position (including restricted cash) decreased by 10.1 million euros from 31.8 million euros at year-end 2015 to 21.7 million euros at the end of June 2016 .Accounting net loss increased from 3.5 million euros in the first half of 2015 to 6.7 million euros in the first half of 2016.  Full Article

More From Around the Web

BRIEF-Pharming Group FY net loss widens to 17.5 million euros

* FY revenue from product sales 13.7 million euros ($14.43 million) versus 8.6 million euros year ago